Dublin, Feb. 16, 2026 (GLOBE NEWSWIRE) — The “Canada Point of Care Molecular Diagnostics Market Research Report 2025-2030” has been added to ResearchAndMarkets.com’s offering.
The Canada Point of Care Molecular Diagnostics Market was valued at USD 350 million in 2024, and is projected to reach USD 560 million by 2030, rising at a CAGR of 8.15%.
The Canada point-of-care molecular diagnostics market in 2025 was characterized by rapid adoption of decentralized testing, strong emphasis on clinical accuracy, and alignment with Health Canada’s regulatory frameworks.
The shift toward decentralized models has been accelerated by the need for timely diagnosis in both primary care and long-term care facilities, enabling clinicians to make faster treatment decisions and improve patient outcomes. Market growth is primarily driven by infectious disease monitoring, including influenza, RSV, and COVID-19, which remain high-priority areas due to seasonal surges and ongoing pandemic preparedness efforts.
Additionally, while oncology biomarkers and women’s health diagnostics are still emerging within the POCT segment, these areas are gaining attention as technological advancements make rapid, minimally invasive testing more feasible outside centralized laboratories. Multinational players lead with advanced platforms and strong regulatory compliance, while mid-sized and emerging vendors focus on multiplex testing, faster results, and digital health integration.
CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET REGIONAL ANALYSIS
Canada’s healthcare system is increasingly adopting POC molecular diagnostics to quickly identify infectious agents such as viruses and bacteria. These rapid testing platforms allow hospitals and clinics to reduce turnaround times, manage patient flow more efficiently, and respond promptly to outbreaks, ensuring better patient outcomes and the containment of infectious diseases.
Ontario dominates with the largest share of the Canada point-of-care molecular diagnostics market. Ontario serves as the primary hub for POC molecular diagnostics in Canada owing to the concentration of major hospitals, teaching institutions, and research centers in cities such as Toronto, Ottawa, and Hamilton. The province’s healthcare infrastructure and high patient volumes make it an ideal market for rapid diagnostic adoption.
Ontario is integrating POC molecular diagnostic devices into community clinics, long-term care facilities, and emergency departments. For example, the Abbott ID NOW system is widely used in urgent care centers across Toronto and Ottawa to provide rapid COVID-19 and influenza results, allowing clinicians to make immediate treatment decisions without sending samples to centralized labs.
Hospitals and healthcare networks in Ontario are incorporating POC devices into Electronic Health Record (EHR) systems. The Sunnybrook Health Sciences Centre uses connected GeneXpert systems that automatically upload test results to patient records, enabling the real-time tracking of infectious disease cases as well as improving coordination between testing sites and physicians.
Quebec is rapidly expanding its adoption of Point-Of-Care (POC) molecular diagnostics, supported by a strong provincial healthcare network, research-driven hospitals, and emerging biotech clusters. The province focuses on improving patient care through rapid diagnostics and expanding testing access beyond major urban centers.
Aging Population Demographics
The population in Canada is aging rapidly, and this demographic shift is becoming one of the strongest drivers for the molecular diagnostics Point-of-Care (PoC) testing industry. As life expectancy increases and chronic diseases become more common among older adults, the demand for faster, more accurate, and accessible diagnostic solutions will grow.
Infectious Disease Outbreak Preparedness
In 2025, Canada is experiencing a resurgence of infectious diseases including measles, respiratory viruses, and foodborne illnesses. These outbreaks have highlighted the urgent need for rapid and accurate diagnostic tools to manage and control the spread of infections. Molecular diagnostics at the Point Of Care (POC) have become indispensable in this context, enabling the timely detection, immediate intervention, and effective containment of outbreaks.
CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET DRIVERS
Digital Health Integration
Canada is witnessing a significant transformation in its healthcare landscape, driven by the integration of digital health technologies into Point-Of-Care (POC) molecular diagnostics. This convergence is enhancing the efficiency, accessibility, and accuracy of medical testing, aligning with the country’s commitment to innovative and patient-centered care.
The demand for at-home diagnostic solutions has surged, reflecting a shift toward decentralized healthcare. For instance, in April 2025, BioSyent Inc. launched a digital platform to distribute at-home diagnostic kits for cholesterol and fertility testing nationwide. This initiative empowers patients to manage their health proactively, reducing the need for frequent clinic visits and alleviating pressure on healthcare facilities.
In March 2025, LifeLabs expanded its molecular diagnostics service offering in Ontario with a new multiplex PCR respiratory panel for RSV, COVID-19, and influenza. This advancement allows healthcare providers to simultaneously detect multiple pathogens from a single sample, facilitating rapid and accurate diagnosis, particularly during peak respiratory illness seasons.
Personalized Medicine Applications
Pharmacogenomics, the study of how genes affect a person’s response to drugs, is increasingly being incorporated into clinical practice across Canada. In 2025, several provinces including British Columbia and Alberta have initiated programs integrating pharmacogenomic testing into routine care. These programs allow healthcare providers to prescribe medications based on a patient’s genetic profile, enhancing drug efficacy and minimizing adverse reactions. For example, patients with certain genetic variants may receive alternative medications that are more effective or have fewer side effects.
Artificial Intelligence (AI) is revolutionizing personalized medicine by enabling the rapid and accurate analysis of complex molecular data. In 2025, Canadian companies including BioAro Inc. are developing AI-guided software platforms that analyze multi-omics data including genomics, proteomics, and metabolomics to provide real-time insights into patient health. These platforms assist healthcare providers in making informed decisions about personalized treatment plans, improving patient outcomes, and optimizing resource utilization.
The Canadian government is actively supporting the integration of personalized medicine into healthcare through policy development and funding initiatives. In 2025, Health Canada introduced regulatory frameworks to facilitate the approval and reimbursement of personalized diagnostic tests and treatments. These policies aim to streamline the adoption of personalized medicine, making it more accessible to patients across the country. Additionally, funding programs are available to support research and development in this field, fostering innovation and ensuring that Canada remains at the forefront of personalized healthcare.
INDUSTRY RESTRAINTS
Healthcare Budget Constraints
Budget constraints in the Canadian healthcare system can impact the adoption of new in-vitro diagnostic tests. Limited funding may restrict healthcare facilities from investing in advanced diagnostic technologies, affecting market growth. For instance, the capital budgets allocated for molecular diagnostics are limited, with an average annual budget of $1,000,000 for equipment and resources.
A 2025 systematic review flagged infrastructure gaps and staffing shortages as the key barriers to community-based molecular testing. Advanced molecular and digital platforms require specialized operators, yet expertise is unevenly distributed. The certification frameworks advocated by the Canadian Society of Clinical Chemists underscore the training burden for widespread point-of-care deployment.
The shortage of skilled laboratory professionals with expertise in performing and interpreting complex in-vitro diagnostic tests can impede market expansion. Adequate training and education programs are crucial to address this challenge. For example, a 2025 systematic review flagged infrastructure gaps and staffing shortages as the key barriers to community-based molecular testing.
KEY QUESTIONS ANSWERED
- How big is the Canada point-of-care molecular diagnostics market?
- What is the growth rate of the Canada point-of-care molecular diagnostics market?
- What are the key trends in the Canada point-of-care molecular diagnostics market?
- Who are the major players in the Canada point-of-care molecular diagnostics market?
- Which region dominates the Canada point-of-care molecular diagnostics market?
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 184 |
| Forecast Period | 2024 – 2030 |
| Estimated Market Value (USD) in 2024 | $350 Million |
| Forecasted Market Value (USD) by 2030 | $560 Million |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Canada |
Market Dynamics
Introduction
- The chapter provides a detailed analysis of the factors driving the market forward.
- It sets the stage for understanding the significant aspects influencing market forces.
Market Opportunities and Trends
- Technological advancements are opening new prospects in the market.
- Increasing demand for innovative solutions is driving the trend for innovation.
- Consumer preferences are rapidly evolving, creating fresh opportunities for growth.
Growth Enablers
- Government initiatives and favorable policies are crucial enablers for market growth.
- Investments in research and development contribute significantly to market advancement.
- Capacity expansion and infrastructure development play a key role in facilitating growth.
Market Restraints
- Stringent regulations may pose challenges to market entry and expansion.
- High operational costs can limit the pace of growth within the market.
- Competitive pressures from established players can restrict new entrants.
Market Landscape
- The competitive landscape is shaped by diverse players vying for market share.
- Market dynamics are influenced by changing consumer demands and innovation.
Key Company Profiles
- Roche Diagnostics Canada
- Abbott Laboratories
- BioMerieux
- Becton Dickinson and Company (BD)
- QIAGEN
- Cepheid
- Hologic
- Thermo Fisher Scientific
- DiaSorin S.p.A.
Other Prominent Company Profiles
- Bioscience Inc.
- MedMira Inc.
- Bio-Rad Laboratories
- Agilent Technologies
- Illumina, Inc
- Grifols, S.A.
- Siemens Healthineers
- Sysmex Corporation
- LifeLabs
- SQI Diagnostics Inc
Segmentation by Diagnostic
- Nucleic Acid Amplification Tests
- Microfluidics and Lab-on-a-Chip Technologies
- CRISPR-based Molecular POC
- Others
Segmentation by Nucleic Acid Amplification-Based POC
- RT-PCR-based Molecular POC
- Loop-mediated Isothermal Amplification
Segmentation by Assay Format
- Simplex Assays
- Duplex Panels
- Triplex Panels
- Multiplex/Syndromic Panels
Segmentation by Application Area
- Respiratory infections
- Sexually transmitted infections (STIs & HIV)
- Tuberculosis (TB) diagnostics
- Bloodstream infections (BSI)
- Hepatitis B & C diagnostics
- Urinary tract infections (UTIs)
- Gastroenteric infections
- Blood yeast (fungal BSI) diagnostics
- Infectious Diseases Testing
- Others
Segmentation by End User
- Hospitals and Health Systems
- Clinical Laboratories
- Physician Offices and Outpatient Clinics
- Urgent Care and Walk-in Clinics
- Long-Term Care Facilities
- Remote and Rural Healthcare Settings
- Public Health Laboratories
- Others
Segmentation by Geography
- Ontario
- Quebec
- British Columbia
- Alberta
- Atlantic Provinces
- Northern Territories
- Others
For more information about this report visit https://www.researchandmarkets.com/r/8oqg0r
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Canadian Point of Care Molecular Diagnostics Market
